{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malaria%2C+Vivax",
    "query": {
      "condition": "Malaria, Vivax"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 13,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malaria%2C+Vivax&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-26T06:12:15.260Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06607003",
      "title": "Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malaria"
      ],
      "interventions": [
        {
          "name": "P. vivax challenge agent derived from PvHMB-CCE001",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "54 Years",
        "sex": "ALL",
        "summary": "18 Years to 54 Years"
      },
      "enrollment_count": 300,
      "start_date": "2024-11-26",
      "completion_date": "2027-11-26",
      "has_results": false,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-06-26T06:12:15.260Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06607003"
    },
    {
      "nct_id": "NCT02751294",
      "title": "A Study to Assess the Effects of Dissolution Profile on the Pharmacokinetics of Single Oral Doses of Tafenoquine Tablets and Tafenoquine Stable Isotope Labelled Solution",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malaria, Vivax"
      ],
      "interventions": [
        {
          "name": "Tafenoquine Control",
          "type": "DRUG"
        },
        {
          "name": "Tafenoquine dissolution profile X",
          "type": "DRUG"
        },
        {
          "name": "Tafenoquine SIL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 14,
      "start_date": "2016-05",
      "completion_date": "2016-08",
      "has_results": false,
      "last_update_posted_date": "2017-01-20",
      "last_synced_at": "2026-06-26T06:12:15.260Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02751294"
    },
    {
      "nct_id": "NCT02658435",
      "title": "Assessment of Any Potential Retinal Effects of Tafenoquine (TQ)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malaria, Vivax"
      ],
      "interventions": [
        {
          "name": "Tafenoquine 150 mg",
          "type": "DRUG"
        },
        {
          "name": "Matched placebo 150mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 486,
      "start_date": "2016-02-02",
      "completion_date": "2017-09-14",
      "has_results": false,
      "last_update_posted_date": "2018-03-01",
      "last_synced_at": "2026-06-26T06:12:15.260Z",
      "location_count": 3,
      "location_summary": "Glendale, California • Overland Park, Kansas • Baltimore, Maryland",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02658435"
    },
    {
      "nct_id": "NCT01928914",
      "title": "Tafenoquine Thorough QTc Study in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malaria, Vivax"
      ],
      "interventions": [
        {
          "name": "Tafenoquine 300mg",
          "type": "DRUG"
        },
        {
          "name": "Tafenoquine 600mg",
          "type": "DRUG"
        },
        {
          "name": "Tafenoquine 1200mg",
          "type": "DRUG"
        },
        {
          "name": "moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Tafenoquine",
          "type": "DRUG"
        },
        {
          "name": "Placebo for moxifloxaxin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 260,
      "start_date": "2011-07-26",
      "completion_date": "2012-06-04",
      "has_results": false,
      "last_update_posted_date": "2017-06-12",
      "last_synced_at": "2026-06-26T06:12:15.260Z",
      "location_count": 2,
      "location_summary": "Culver City, California • Baltimore, Maryland",
      "locations": [
        {
          "city": "Culver City",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01928914"
    },
    {
      "nct_id": "NCT00935623",
      "title": "Clinical Trial for the Development of a Safe Malaria Challenge Model That Can be Reproduced in Humans",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Plasmodium Vivax Malaria"
      ],
      "interventions": [
        {
          "name": "Malaria Challenge",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 12,
      "start_date": "2009-04-21",
      "completion_date": "2011-09",
      "has_results": false,
      "last_update_posted_date": "2018-08-16",
      "last_synced_at": "2026-06-26T06:12:15.260Z",
      "location_count": 1,
      "location_summary": "Silver Spring, Maryland",
      "locations": [
        {
          "city": "Silver Spring",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00935623"
    },
    {
      "nct_id": "NCT00295581",
      "title": "PpPfs25/ISA51 and ScPvs25/ISA51 Vaccines for Malaria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Plasmodium Falciparum",
        "Plasmodium Vivax Malaria"
      ],
      "interventions": [
        {
          "name": "PpPfs25/ISA51 & ScPvs25/ISA51",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 0,
      "start_date": "2005-03-07",
      "completion_date": "2008-06-17",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-06-26T06:12:15.260Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Bethesda, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00295581"
    },
    {
      "nct_id": "NCT02960568",
      "title": "Genetic Variability in CYP2D6 in U.S Active Duty Population",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pharmacologic Action"
      ],
      "interventions": [
        {
          "name": "Primaquine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Walter Reed Army Institute of Research (WRAIR)",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 550,
      "start_date": "2016-01-08",
      "completion_date": "2017-08",
      "has_results": false,
      "last_update_posted_date": "2021-10-20",
      "last_synced_at": "2026-06-26T06:12:15.260Z",
      "location_count": 1,
      "location_summary": "Silver Spring, Maryland",
      "locations": [
        {
          "city": "Silver Spring",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02960568"
    },
    {
      "nct_id": "NCT00928083",
      "title": "A Study to Investigate the Safety, Tolerability and Pharmacokinetics of OZ439 in Healthy Male and Female Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malaria Falciparum",
        "Malaria Vivax",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "OZ439 50mg API capsules",
          "type": "DRUG"
        },
        {
          "name": "OZ439 200mg API capsules",
          "type": "DRUG"
        },
        {
          "name": "OZ439 400mg aqueous dispersion",
          "type": "DRUG"
        },
        {
          "name": "OZ439 800mg aqueous dispersion",
          "type": "DRUG"
        },
        {
          "name": "OZ439 100mg API capsules",
          "type": "DRUG"
        },
        {
          "name": "OZ439 400mg API capsules",
          "type": "DRUG"
        },
        {
          "name": "OZ439 1600mg aqueous dispersion",
          "type": "DRUG"
        },
        {
          "name": "OZ439 800mg API capsules",
          "type": "DRUG"
        },
        {
          "name": "OZ439 1200mg API capsules",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "OZ439 200mg aqueous dispersion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medicines for Malaria Venture",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 63,
      "start_date": "2009-04",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2015-01-08",
      "last_synced_at": "2026-06-26T06:12:15.260Z",
      "location_count": 1,
      "location_summary": "Miramar, Florida",
      "locations": [
        {
          "city": "Miramar",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00928083"
    },
    {
      "nct_id": "NCT05913973",
      "title": "Study of the Plasmodium Vivax Transmission-blocking Vaccine Pvs230D1-EPA/Matrix-M to Assess Safety, Immunogenicity, and Transmission-blocking Activity in Healthy Malaria-naive Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malaria"
      ],
      "interventions": [
        {
          "name": "Pvs230D1-EPA/Matrix-M",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 105,
      "start_date": "2023-08-04",
      "completion_date": "2025-11-12",
      "has_results": false,
      "last_update_posted_date": "2025-12-01",
      "last_synced_at": "2026-06-26T06:12:15.260Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05913973"
    },
    {
      "nct_id": "NCT02184637",
      "title": "A Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine Co-administered With Either Artemether + Lumefantrine or Dihydroartemisinin + Piperaquine Tetraphosphate",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malaria, Vivax"
      ],
      "interventions": [
        {
          "name": "Tafenoquine",
          "type": "DRUG"
        },
        {
          "name": "Dihydroartemisinin + Piperaquine tetraphosphate",
          "type": "DRUG"
        },
        {
          "name": "Artemether + Lumefantrine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 120,
      "start_date": "2014-07-31",
      "completion_date": "2015-04-08",
      "has_results": false,
      "last_update_posted_date": "2017-07-13",
      "last_synced_at": "2026-06-26T06:12:15.260Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02184637"
    }
  ]
}